Exploring The Alarming Surge Of Life Threatening Events Linked To Mavacamten- Analysis Of FDA Adverse Event Reporting System Database
Mavacamten is a novel cardiac myosin ATPase inhibitor targeted for treatment of hypertrophic obstructive cardiomyopathy (HOCM). It acts by formation of actin-myosin cross-bridge thus reducing contractility and improving myocardial energetics. Since its approval in April 2022 by the U.S. Food and Drug Administration (FDA), it has been popular for treatment of patients with symptomatic New York Heart Association (NYHA) class II-III HOCM. During review by FDA, mavacamten exhibited a side effect profile of heart failure (HF) that was deemed significant enough to warrant as a boxed warning.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Resha Khanal, Kripa Rajak, Rajendra Shah, Anupam Halder, Kriti Kalra, Saman Razzaq, Binita Bhandari, Sristee Niraula, Shital Oli, Sharad Oli Tags: 236 Source Type: research